Advertisement
Screener

SOLVENTUM CORPORATION (SOLV) Deferred Revenue Recognized

2.8 / 5 stars · 68/120 Roast Me

SOLVENTUM CORPORATION Deferred Revenue Recognized

SOLVENTUM CORPORATION (SOLV) reported Deferred Revenue Recognized of $189.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Income Statement › Other Income

us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-05

  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2026-06-30 was $189.00M, a 18.87% increase year-over-year.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $226.00M, a 2.73% increase year-over-year.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $98.00M, a 10.91% decline year-over-year.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $159.00M, a 6.00% increase year-over-year.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for fiscal 2025 was $550.00M, a 0.00% change from fiscal 2024.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for fiscal 2024 was $550.00M, a 1.85% increase from fiscal 2023.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for fiscal 2023 was $540.00M, a 0.00% change from fiscal 2022.
  • SOLVENTUM CORPORATION contract with customer, liability, revenue recognized for fiscal 2022 was $540.00M.
Period endContract with Customer, Liability, Revenue Recognized 3 monthContract with Customer, Liability, Revenue Recognized 6 monthContract with Customer, Liability, Revenue Recognized 9 monthContract with Customer, Liability, Revenue Recognized 12 month
2026-06-30$189.00M
10-Q · filed 2026-08-05
$416.00M
10-Q · filed 2026-08-05
2026-03-31$226.00M
10-Q · filed 2026-05-05
2025-12-31$550.00M
10-K · filed 2026-02-27
2025-09-30$98.00M
10-Q · filed 2025-11-06
$477.00M
10-Q · filed 2025-11-06
2025-06-30$159.00M
10-Q · filed 2026-08-05
$379.00M
10-Q · filed 2026-08-05
2025-03-31$220.00M
10-Q · filed 2026-05-05
2024-12-31$550.00M
10-K · filed 2026-02-27
2024-09-30$110.00M
10-Q · filed 2025-11-06
$500.00M
10-Q · filed 2025-11-06
2024-06-30$150.00M
10-Q · filed 2025-08-08
$390.00M
10-Q · filed 2025-08-08
2024-03-31$240.00M
10-Q · filed 2025-05-09
2023-12-31$540.00M
10-K · filed 2026-02-27
2023-09-30$115.00M
10-Q · filed 2024-11-08
$475.00M
10-Q · filed 2024-11-08
2023-06-30$155.00M
10-Q · filed 2024-08-09
$360.00M
10-Q · filed 2024-08-09
2023-03-31$205.00M
10-Q · filed 2024-05-10
2022-12-31$540.00M
10-K · filed 2025-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Penumbra Inc (PEN)United States$12.596B77.33
BAXTER INTERNATIONAL INC (BAX)United States$12.139B-10.35
GLOBUS MEDICAL INC (GMED)United States$9.977B20.03
INSULET CORP (PODD)United States$9.420B28.12
GLAUKOS Corp (GKOS)United States$9.135B-43.73
MiniMed Group, Inc. (MMED)United States$5.748B-16.85
MERIT MEDICAL SYSTEMS INC (MMSI)United States$5.212B28.44
TELEFLEX INC (TFX)United States$5.093B-5.44
HAEMONETICS CORP (HAE)United States$4.821B36.52
Heartflow, Inc. (HTFL)United States$4.225B